Arcellx (ACLX) | Financial Analysis & Statements
Arcellx Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
1.7M
Operating Income
-63.7M
-3,850.24%
Net Income
-58.1M
-3,513.42%
Balance Sheet Metrics
Total Assets
604.0M
Total Liabilities
201.6M
Shareholders Equity
402.4M
Debt to Equity
0.50
Cash Flow Metrics
Operating Cash Flow
-41.0M
Free Cash Flow
-58.9M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Arcellx Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 22.3M | 107.9M | 110.3M | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 157.6M | 157.1M | 133.8M | 149.6M | 46.9M |
| Selling, General & Administrative | 117.8M | 88.4M | 66.4M | 41.7M | 18.1M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 275.4M | 245.5M | 200.2M | 191.3M | 65.0M |
| Operating Income | -253.1M | -137.6M | -89.9M | -191.3M | -65.0M |
| Operating Margin % | -1,135.6% | -127.5% | -81.5% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 24.2M | 33.3M | 23.7M | 4.3M | 59.0K |
| Interest Expense | 0 | 1.0M | 3.8M | 1.7M | 10.0K |
| Other Non-Operating Income | - | - | - | - | 49.0K |
| Pre-tax Income | -228.9M | -105.3M | -70.0M | -188.7M | -65.0M |
| Income Tax | 69.0K | 2.1M | 663.0K | 0 | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -228.9M | -107.3M | -70.7M | -188.7M | -65.0M |
| Net Margin % | -1,027.3% | -99.5% | -64.1% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -222.2M | -99.1M | -64.1M | -185.6M | -63.9M |
| EPS (Basic) | - | $-2.00 | $-1.47 | $-5.19 | $-1.94 |
| EPS (Diluted) | - | $-2.00 | $-1.47 | $-5.19 | $-1.94 |
| Basic Shares Outstanding | - | 53566153 | 48061450 | 36355758 | 33543534 |
| Diluted Shares Outstanding | - | 53566153 | 48061450 | 36355758 | 33543534 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Arcellx Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 80.3M | 105.7M | 394.6M | 64.2M | 30.8M |
| Short-term Investments | 370.1M | 481.7M | 307.4M | 190.7M | 73.8M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 7.8M | 5.8M | 5.7M | 3.7M | 2.0M |
| Total Current Assets | 462.2M | 599.3M | 716.4M | 266.9M | 112.8M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 42.6M | 40.1M | 39.3M | 39.0M | 9.8M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 5.6M | 3.5M | 11.8M | 7.1M | 5.7M |
| Total Non-Current Assets | 141.8M | 112.0M | 108.8M | 47.0M | 16.0M |
| Total Assets | 604.0M | 711.3M | 825.1M | 313.8M | 128.8M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 5.6M | 2.1M | 2.6M | 9.1M | 1.3M |
| Short-term Debt | 7.6M | 7.5M | 46.8M | 36.0M | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 4.4M | 8.5M | 8.2M | 3.1M | 2.0M |
| Total Current Liabilities | 104.2M | 125.4M | 118.2M | 56.7M | 14.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 44.3M | 46.5M | 50.8M | 52.2M | 0 |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | 8.6M | - | - | 178.0K |
| Total Non-Current Liabilities | 97.4M | 131.1M | 221.5M | 52.2M | 235.5M |
| Total Liabilities | 201.6M | 256.5M | 339.8M | 108.9M | 250.3M |
| Equity | |||||
| Common Stock | 56.0K | 53.0K | 52.0K | 44.0K | 1.0K |
| Retained Earnings | -725.8M | -496.8M | -389.5M | -318.8M | -130.1M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 402.4M | 454.8M | 485.4M | 205.0M | -121.5M |
| Key Metrics | |||||
| Total Debt | 51.9M | 54.1M | 97.6M | 88.1M | 0 |
| Working Capital | 358.0M | 473.9M | 598.1M | 210.2M | 98.0M |
Balance Sheet Composition
Arcellx Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -228.9M | -107.3M | -70.7M | -188.7M | -65.0M |
| Depreciation & Amortization | 6.7M | 5.2M | 2.0M | 1.3M | 1.0M |
| Stock-Based Compensation | 77.9M | 61.1M | 41.8M | 21.5M | 6.8M |
| Working Capital Changes | -33.8M | -81.4M | 228.2M | 10.5M | 1.0M |
| Operating Cash Flow | -178.2M | -118.4M | 221.2M | -91.1M | -56.2M |
| Investing Activities | |||||
| Capital Expenditures | -2.3M | -13.4M | -21.4M | -2.3M | -5.8M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -407.0M | -597.3M | -442.4M | -273.7M | -74.2M |
| Investment Sales | 495.6M | 427.7M | 309.3M | 158.3M | 0 |
| Investing Cash Flow | 86.3M | -183.0M | -154.5M | -117.7M | -80.0M |
| Financing Activities | |||||
| Share Repurchases | - | - | 0 | 0 | -24.0K |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | -230.0K | -39.8M | -29.4M | -9.7M | -387.0K |
| Financing Cash Flow | 92.9M | -39.8M | 270.3M | 250.2M | 118.0M |
| Free Cash Flow | -212.6M | -96.9M | 186.1M | -101.6M | -60.0M |
| Net Change in Cash | 958.0K | -341.3M | 337.0M | 41.4M | -18.1M |
Cash Flow Trend
Arcellx Key Financial Ratios
Valuation Ratios
Forward P/E
-66.41
Price to Book
16.56
Price to Sales
301.85
PEG Ratio
-66.41
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-3,850.24%
Return on Equity
-53.42%
Return on Assets
-24.05%
Financial Health
Current Ratio
4.44
Debt to Equity
12.90
Beta
0.25
Per Share Data
EPS (TTM)
$-4.07
Book Value per Share
$6.95
Revenue per Share
$0.40
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ACLX | 6.7B | - | 16.56 | -53.42% | 0.00% | 12.90 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






